FDA Brief

Warning letters Devices

FDA warning letter to

Jiangsu Caina Medical Co., Ltd

High riskIssued Jul 18, 2024Posted Jul 18, 2024Center for Devices and Radiological Health

Jiangsu Caina Medical made Monoject sterile syringes for Cardinal Health but did not properly investigate pump-incompatibility complaints, leading to a Class I recall.

What happened

FDA inspected the firm's facility in Jiangyin City, Jiangsu, China, from March 11 through March 23, 2024. Investigators found that starting in July 2023 the firm received at least 41 US complaints that its sterile syringes were not recognized by, or did not work with, syringe pumps, and that the firm closed the complaints without opening a corrective action (CAPA). FDA also found the firm's risk analysis for the syringes did not include the hazard of pump use, and that it did not submit required reports for malfunctions that may have caused serious injury or death.

What FDA found

  1. The firm did not analyze complaint data to spot causes of nonconforming product or other quality problems.

    21 CFR 820.100(a)(1)
  2. The firm did not investigate the cause of nonconformities, including complaints of pump incompatibility and inaccurate dosing.

    21 CFR 820.100(a)(2)
  3. The firm's risk analysis for the syringes did not include the hazard of use in an infusion pump, and the risk controls it listed were not verified as implemented or effective.

    21 CFR 820.30(g)
  4. The firm did not submit reports to FDA within 30 calendar days for device malfunctions that could contribute to death or serious injury.

    21 CFR 803.50(a)(2)

What FDA wants

FDA asks the firm to reply in writing within fifteen business days describing the specific steps taken to fix the violations, how it will prevent recurrence, and a timetable for any actions not yet complete. FDA also says the firm's syringes are subject to detention without physical examination at the US border until the violations are addressed.

Who should pay attention

  • brands and distributors that buy private-label syringes from contract manufacturers
  • hospital staff and clinicians who select syringes for infusion and enteral pumps
  • quality teams that handle complaints, CAPA and FDA malfunction reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk